Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM
AI Summary
Lexicon Pharmaceuticals shares surged after Cantor Fitzgerald cited an unencumbered path in hypertrophic cardiomyopathy (HCM). The headline suggests a favorable analyst view of the company’s prospects in this therapeutic area, but provides no further detail.